HBeAg seroconversion at the end of 1 year was 29% for combination, 18% for lamivudine, 19% for interferon and 4% in placebo.
HBeAg seroconversion at the end of 1 year was 29% for combination, 18% for lamivudine, 19% for interferon and 4% in placebo.
治疗一年后，HBEAG血清转换情况为：联合治疗为29%，拉米夫啶为18%，干扰素为19%，安慰组为4%。